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INTRODUCTION
Gemcitabine (Gemzar, 2′,2′-difluorodeoxycytidine,
dFdC) is one of the most promising agents for the treatment
of solid tumors. The drug has good activity as a single agent
and excellent activity in combination therapy against several
resistant tumors such as non-small cell lung cancer (NSCLC)
and pancreatic cancer. Gemcitabine is a deoxycytidine ana-
log with structural resemblance to cytarabine (ara-C) which
is the most effective agent in adult acute leukemias [1], but
which does not show activity against solid tumors as does
gemcitabine. This might be due to the multiple mechanisms
of action of gemcitabine [2]. Gemcitabine membrane trans-
port is mediated by the facilitated nucleoside transporter [3].
Subsequently, it is phosphorylated to its mononucleotide by
deoxycytidine kinase [4] and by nucleotide kinases to its
active metabolite, gemcitabine triphosphate (dFdCTP). A
strong correlation between the activation of gemcitabine, the
extent of dFdCTP formation, its incorporation into DNA, and
its inhibition of DNA synthesis was found [3, 5-7].
Furthermore, gemcitabine can be incorporated into RNA [6]
and can induce apoptosis [8]. Other effects of metabolites of
gemcitabine include inhibition of ribonucleotide reductase
and dCMP deaminase [9] enhancing the incorporation of
dFdCTP into DNA. Gemcitabine exhibits excellent preclini-
cal activity against xenografts of lung, breast, head and
neck, colon, and ovarian cancers. This activity was very
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ABSTRACT
Gemcitabine (2′,2′-difluorodeoxycytidine, Gemzar) is
a deoxycytidine analog with excellent antitumor activity
against a number of solid tumors. Gemcitabine needs to
be activated by deoxycytidine kinase and other kinases to
its triphosphate, gemcitabine triphosphate, which can be
incorporated into RNA and DNA. The latter effect is con-
sidered to be responsible for its antitumor effect and
causes masked chain termination and inhibition of DNA
repair. This effect may be of importance for combination
with DNA interacting agents. In phase I trials daily, twice
weekly, weekly and every two weeks schedules have been
evaluated. At the weekly schedule of 1,000-1,250 mg/m2
significant antitumor activity was observed in bladder,
breast, ovary, and pancreatic cancer, non-small cell lung
cancer (NSCLC), and small cell lung cancer of 31%,
33%, 22%, 11%, 22% and 27% total response rates,
respectively. Gemcitabine also showed considerable
improvement in clinical symptoms, while toxicity was
not severe with mild myelosuppression. Due to its abil-
ity to inhibit DNA replication, combination studies were
initiated with DNA damaging agents. For the various
combinations with cisplatin in phase II studies on
NSCLC, response rates varied from 42%-54%, with a
median survival of generally more than 12 months.
Also, combinations with taxanes, etoposide, doxorubicin
and vindesin seem promising. Gemcitabine is an impor-
tant agent for the management of several relatively
chemoresistant cancer types, both with respect to anti-
tumor activity and clinical benefit. Future research on
combination studies deserves high priority considering
the high response rates in NSCLC and bladder cancer.
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schedule-dependent [10-15], which could be a key issue for
further clinical development, when translated properly. 
PHASE I STUDIES
In phase I trials, several schedules with gemcitabine have
been studied. The daily × 5 schedule [16] with a maximally
tolerated dose ( MTD) of 9 mg/m2 caused fever, a flu-like syn-
drome, and life-threatening hypotension. In the twice-weekly
schedule [17], the maximum tolerated dose of gemcitabine
was 150 mg/m2, and flu-like symptoms with fever, rigors, and
malaise were observed. Neither schedule was recommended
for phase II studies. In other phase I studies, the drug was
administered as a weekly or every two weeks 30 min infusion,
in which the drug was extremely well tolerated, with dose-lim-
iting toxicity appearing to be mainly myeloid; however, lethar-
gy, mild flu-like symptoms, and a reversible skin rash were
also found [18-20]. The MTD of gemcitabine in the weekly
schedule was 790 to 1,500 mg/m2. The every two weeks
schedule was not recommended for phase II studies, although
in several combination studies (e.g., with paclitaxel [21]),
gemcitabine was given every two weeks. The initial schedule
for phase II studies was a 30 min infusion of 800 mg/m2 (days
1, 8, 15 every four weeks) which was increased to 1,000-1,250
mg/m2 due to lack of toxicity in most patients. 
A better understanding of the clinical pharmacology and
the good tolerability of gemcitabine in most phase I studies
have led to a second generation of phase I trials that attempt-
ed to increase dose intensity, either by escalating the dose or
by an increase of the infusion duration. For most of these
studies, the weekly schedule of gemcitabine was used. In
general, the dose-escalating studies have demonstrated that
gemcitabine doses of 1,250 to 2,800 mg/m2 can be safely
administered to chemotherapy-naive patients in good over-
all condition, with myelosuppression as the main toxicity at
the higher doses; however, additional toxicities such as
reversible increase in hepatic transaminases and proteinuria
were also observed [22]. A randomized study comparing
1,250 with 2,500 mg/m2 gemcitabine (days 1, 8, 15) will elu-
cidate whether dose escalation will result in improved effi-
cacy in NSCLC. It is, however, possible that at 1,250 mg/m2
saturation of gemcitabine triphosphate will be observed,
although from preclinical studies it may be concluded that
for certain diseases, dose escalation might be effective [15].
An increase of infusion time to 24 h was studied by
Anderson et al. in patients with NSCLC [23]. The MTD was
180 mg/m2 with dose-limiting neutropenia and lethargy. In
this phase I study, 21% of patients (95% confidence interval:
7% to 42%) achieved a partial response. This interesting
result is in accordance with an in vivo study in murine colon
tumors [15], which suggests better antitumor activity of a
weekly 24-h infusion of gemcitabine compared to a bolus
administration. However, the disadvantage of this schedule
is a considerable dose reduction (1,000 to 180 mg/m2 in
patients and 120 to 15 mg/kg in mice), which may result in
a too low gemcitabine triphosphate accumulation.
In two studies, the effect of increasing the duration of
infusion with a constant dose of gemcitabine was studied
following the finding that in most human tumor cell lines
and xenografts, accumulation of gemcitabine triphosphate
was dependent on the total time of exposure [2, 3, 9, 24, 25].
In one study, the dose was kept constant and only the dura-
tion of infusion was prolonged up to 270 min in patients
with solid tumors [26]. The MTD was reached with week-
ly doses of 300 mg/m2 for a 270 min infusion, with myelo-
suppression as the dose-limiting toxicity. In a study in
which only the dose rate was kept constant, the duration of
infusion was prolonged up to 480 min (constant infusion
rate: 10 mg/m2/min) every three weeks in leukemia patients
[27] with an MTD of 4,800 mg/m2. At these gemcitabine
doses, gemcitabine triphosphate levels reached the saturation
limits of mononuclear and leukemia cells. Unfortunately, the
antileukemia activity in this study, as determined by reduc-
tion of the percentage of blasts in the marrow, was disap-
pointing. However, this might have been a result of reduction
of the intensity of the chemotherapy. A more focused schema
in which gemcitabine is infused at more frequent intervals
will further elucidate the activity of gemcitabine in leukemia. 
PHASE II STUDIES
Most phase II studies have been performed utilizing the
weekly schedule (days 1, 8 and 15) with a 30 min infusion,
repeated every four weeks at 800 to 1,250 mg/m2 (Table 1).
Excellent activity has been found in several tumors usually
not responsive to chemotherapy. In NSCLC, several studies
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Table 1. Antitumor activity of gemcitabine in phase II studies
Tumor type No. evaluable Mean Reference
patients RR (%)
Bladder 99 31 [20, 29, 30, 31]
Breast 93 33 [32, 33, 34]
SCLC 29 27 [35]
NSCLC 338 22 [22, 36, 37, 38]
Cervix 28 18 [28]
Ovary 111 22 [39, 40, 41]
Head & neck 61 13 [42]
Renal 55 8.1 [43, 44]
Pancreas 139 11 [45, 46, 47]
SCLC: small cell lung cancer
NSCLC: non-small cell lung cancer
RR: response rate
have been performed varying the gemcitabine dosage among
a total of 361 patients. In an early phase II study in the United
States, the results were disappointing, with a response rate of
3%. However, this was mainly due to underdosing of these
patients since the mean and median doses delivered were
both under 750 mg/m2 [48]. In later phase II studies, response
rates of 20% to 22.5% with a mean survival time (MST) of
7.6 to 12.7 months [22, 36-38] have been observed, placing
gemcitabine among the most active single agents in this
notoriously difficult-to-treat cancer type. Interestingly, the
incidence of responders was somewhat higher in females
(24%) than in males (18%), which may be related to the dif-
ferences in metabolism of gemcitabine in males and females
[49]. Moreover, most patients showed an improvement in
performance and symptoms, which were better in this single-
agent treatment than in most currently used combination reg-
imens [50]. In a 90 mg/m2 twice-weekly schedule phase II
study, the response rate was comparable to the once-weekly
schedule studies (19.7%) [51]. However, toxicity occurred in
a higher incidence than with the once-weekly schedule;
therefore, it was concluded that the once-weekly schedule
should be used in preference to the twice-weekly schedule.
Not only in NSCLC were good response rates observed
[52]. In patients with breast cancer treated with 725 mg/m2
gemcitabine, a response rate of 25% was found (95% confi-
dence interval: 12.7% to 41.2%) with an MST of 11.5 months
[35]. In bladder cancer, response rates varying from 27%-
38% were observed both in untreated and pretreated (MVAC
or cisplatin) patients, while in ongoing studies with 1,200
mg/m2, even higher responses of up to 46% were observed.
Less but considerable activity has been documented in ovari-
an, head and neck, and renal cancers [39-44]. In a phase II
study in ovarian cancer patients the response rate was 19%,
but, more important, the responses were observed in a poor
prognostic group of patients, characterized by primary plat-
inum resistance [39]. In patients with NSCLC and pancreat-
ic cancer a decrease in pain, weight gain and improvement in
performance status were observed, suggesting improvement
of quality of life [31, 45, 53]. In a study conducted by
Rothenberg et al. [46] disease-related symptom relief was
used as an endpoint in a phase II study in pancreatic cancer
patients previously treated with 5-fluorouracil (5-FU). A clin-
ical benefit response (CBR) (defined as a 50% or greater
decrease in pain intensity, or a 50% or greater reduction in
daily analgesic consumption, or a 20-point or greater
improvement in Karnofsky status) was achieved in 27% of 63
patients. Subsequently, a randomized single-blind trial of
gemcitabine versus 5-FU was performed showing a 23.8%
versus 4.8% difference in CBR [54], and median survival of
5.7 versus 4.2 months, respectively. In colorectal and gastric
cancer, no significant responses were observed with the
applied schedule [55, 56] in contrast to the results in pre-
clinical models. Overall, the drug was well tolerated. The
most frequent toxic effects were myelosuppression, a mild
flu-like syndrome, nausea, vomiting, and skin rash.
Altogether the phase II studies showed that at its recom-
mended dose, gemcitabine was an active agent in several
chemoresistant cancers. More importantly, gemcitabine was
active in pretreated cisplatin-resistant tumors. Not only in pan-
creatic cancer, but also in NSCLC, an improvement in clinical
symptoms was observed, very much in line with several pre-
clinical studies [15]. These data suggest that the possibilities of
gemcitabine as a single agent have not yet been fully explored.
COMBINATION STUDIES WITH GEMCITABINE
Gemcitabine, because of its inherent ability to inhibit
DNA replication and repair, is an attractive candidate for com-
bination with therapy that causes DNA damage, including
radiation. Preclinical studies have demonstrated synergism
between gemcitabine and cisplatin in ovarian, NSCLC, head
and neck cancer, and colon cancer cell lines [57-61] which is
likely to be related to increased formation of DNA platinum
adducts [59]. Pretreatment with gemcitabine gave the best
results. In vivo studies with head and neck xenografts and
murine colon cancer also demonstrated a schedule-dependent,
at least additive, and in some lines, a more than additive effect
of gemcitabine and cisplatin [57, 60]. In other in vivo studies
with lung xenografts, treatment with cisplatin after the last
dose of gemcitabine also enhanced antitumor activity [61].
Altogether, these studies indicate that more schedules of gem-
citabine and cisplatin might be synergistic. Furthermore, other
studies demonstrated additivity and synergism in some lung
and ovarian cancer cell lines for gemcitabine and etoposide
[62], mitomycin [62], 5-FUdR [63] and LY231514 [62], the
multitargeted antifolate, topotecan, and 5-FU (unpublished
observations).
The mild toxicity profile of gemcitabine at an active
dose together with the nonoverlapping toxicity pattern of
gemcitabine and cisplatin formed the basis for phase I/II
studies of this combination in several malignancies. In all
clinical studies utilizing different schedules of cisplatin and
gemcitabine, an increased activity compared to each agent
alone has been observed in NSCLC (Table 2). This is very
much in line with the preclinical studies and indicates at
least an additive effect. Gemcitabine preceding cisplatin
[66] resulted in 26 partial responses (PR) and 1 complete
response (CR), with an overall response rate of 58% (95%
confidence interval; 44% to 72%) and manageable toxicity.
In none of the phase II studies conducted so far, however,
were response rates below 42% observed, and in all studies
toxicity was primarily hematologic and easily manageable.
It is of interest to note that although these studies were not
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randomized, altogether more than 50% of the patients were
alive after 12 months, compared to six to nine months for
most other regimens currently being employed. Gemcitabine
with cisplatin is also being studied in other malignancies with
encouraging results in pancreatic, ovarian, breast, and bladder
cancers. Although the combination of gemcitabine with cis-
platin is a very interesting treatment for patients with NSCLC,
because of its high response rates and low toxicity, the opti-
mal schedule is not clear. To study this schedule dependency
in more detail in patients, a phase I study was conducted in
which DNA platination and gemcitabine triphosphate accu-
mulation were determined in white blood cells of patients
treated with either gemcitabine (800 mg/m2) four h before cis-
platin (50 mg/m2) or cisplatin four h before gemcitabine [71].
Because no clear differences were found comparing these
treatments, an interval between drugs of 24 h is currently
being studied. Because of the different toxicity profiles of car-
boplatin, several studies are currently being performed in
which the targeted AUC was set at 6 mg/ml/min [70].
Several other combination studies with gemcitabine in
NSCLC include combinations, e.g., with paclitaxel, etopo-
side, or vindesine (Table 3). Response rates in NSCLC in
these ongoing studies are varying, from 21% (epirubicin) to
32% (ifosfamide). Gemcitabine in combination with 5-FU or
hydroxyurea are currently being studied in phase I trials. A
study with the combination of gemcitabine and doxorubicin
is ongoing in advanced breast cancer, with a very promising
response rate of 75% [77].
Gemcitabine has also shown excellent preclinical activity
as a radiosensitizer in colon, pancreas, breast, and head and
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Table 3. Phase I and II combination studies with gemcitabine 
Schedule*
Cancer type No. evaluable patients RR (%) Reference
Phase I MTD**
Paclitaxel*** 75-175 before dFdC# Breast 42 [21]
Paclitaxel 135 (d 8) before dFdC Ovarian 8 17 [72]
Vindesine 3 (weekly × 7) NSCLC 32 27 [73]
Etoposide 80 (d 8, 9, 10) 28 15.6 [74]
Epirubicin 15 (d 1, 8, 15) Breast 12 25 [75]
Phase II
Ifosfamide 1,500 (d 8, 9, 10, 11, 12) NSCLC 50 32 [76]
Doxorubicin 25 (d 1, 8, 15 after dFdC) Breast 24 75 [77]
*** Gemcitabine dosage: 1,000 mg/m2 (d 1, 8, 15).
*** Dosage in mg/m2.
*** Paclitaxel and gemcitabine (q2wks), gemcitabine dosage: 1,500-3,500 mg/m2. 
**# Dose-limiting toxicity (neutropenia and transaminase increase) 175/3,500 mg/m2, recommended phase II doses 150/3,000 mg/m2
(M. Rothenberg, personal communication).
Table 2. Antitumor effect of several schedules of the combination of gemcitabine and platinum compounds in phase I and phase II studies in non-small
cell lung cancer
Schedule
No. evaluable patients RR (%) Median survival Reference
Gemcitabine (mg/m2) Cisplatin (mg/m2) (months)
1,000-1,800 (d 1,8,15) 30 (d 1, 8, 15) 47 30 6 [64]
1,000 (d 1,8,15) 100 (d 15) 43 42 10.2 [65]
1,000 (d 1,8,15) 100 (d 2) 48 54 13 [66]
1,000 (d 1,8,15) 100 (d 1) 26 42 [67]
1,000 (d 1,8,15) 100 (d 15) 50 52 13 [68]
1,200 (d 1,8,15) 100 (d 15 before dFdC) 40 48 10.7 [69]
Carboplatin
1,000 (d 1,8,15) AUC 5.2 mg/ml/min 13 33 11.3 [70]
AUC: Area under the plasma concentration versus time curve.
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neck cancer [78, 79] cell lines. These in vitro studies are
being used as guidelines for development of clinical trials of
gemcitabine with radiation therapy. However, initial studies in
NSCLC showed grade 4 toxicity in seven out of eight patients,
and the study was discontinued [80]. This was considered to
be related to the high gemcitabine dose (1,000 mg/m2) result-
ing in aspecific sensitization of normal tissues; therefore, in
subsequent studies, the dose was reduced to 150-300 mg/m2.
In addition to the doublets which have now been investi-
gated extensively in various malignancies, a couple of logical
triplets have entered clinical trials. These include combina-
tions of gemcitabine, with a platinum and a taxane, etoposide,
ifosfamide, or vinorelbine, or with radiation. These studies
may represent additional problems since the sequence of the
drugs can induce unexpected toxicities. The composition of
the combinations will be determined by the disease, as in the
use of gemcitabine, a platinum, and a taxane for NSCLC,
SCLC, and ovarian cancer. 
FUTURE PROSPECTS
From all studies, it is clear that gemcitabine is a very active
drug in various malignancies. Considering the relatively low
and easily manageable toxicity, it may be concluded that sin-
gle-agent gemcitabine may have been underdosed. It is, how-
ever, possible that for certain diseases there is a maximal
effective dose for gemcitabine. From preclinical studies, there
is evidence that an increase in dose can result in a better anti-
tumor activity in certain tumors but not in other tumors. This
may depend on the drug penetration in solid tumors. Several
clinical studies are under way which address this question for
NSCLC. The efficacy of single-agent gemcitabine may also
have been limited by its schedule. Again, from preclinical
studies in cell lines and animals, there is evidence that prolon-
gation of exposure may enhance its activity; in clinical studies
in which the dose intensity is increased, prolongation of the infu-
sion period up to five to six h may very well increase the accu-
mulation of the active metabolite in the target tumor cell. With a
more prolonged infusion the dose intensity has to be reduced,
probably leading to a reduction of gemcitabine triphosphate.
Single agent gemcitabine, due to its favorable toxicity
profile, is an attractive treatment regimen for several second-
line treatments such as in cisplatin-resistant ovarian and lung
cancers. Optimization of the schedule, however, can change
the drug to a first choice in first-line treatment, especially
when combined with another proper active drug. Randomized
studies such as the ECOG trial comparing Taxol-cisplatin,
taxotere-cisplatin, gemcitabine-cisplatin, and Taxol-gemc-
itabine may provide an answer on the questions which are the
active regimens in NSCLC. Additional attractive treatment
regimens include an alternation of doublets such as carbo-
platin-Taxol, carboplatin-gemcitabine, and cisplatin-topote-
can in ovarian cancer, although the composition of the
doublets and the length of cycles may be debatable.
Disease types in which gemcitabine combinations may
result in a substantial increase in the therapeutic efficacy are
pancreatic cancer and bladder cancer. In pancreatic cancer, the
activity of single-agent gemcitabine warrants the study of
combinations with cisplatin and 5-FU. Ongoing combination
studies with cisplatin also indicate an increased response rate
for the combination. The relatively high activity of single-
agent gemcitabine in second-line treatment of bladder cancer
(25%-30%) and the relatively high activity of gemcitabine-cis-
platin in ongoing studies (45%-70%) warrant future studies in
comparison with the MVAC schedule in this disease.
Similarly, combinations with doxorubicin in breast cancer are
warranted.
An important issue in the combinations with cisplatin is
the scheduling. From the various clinical studies, it appears
that more schedules are active; however, the schedule in which
cisplatin is given one day after the last gemcitabine dose is less
toxic. In most schedules in which cisplatin is given at day 1 or
2 or at days 1 and 7, the last dose at day 15 cannot be given due
to increased toxicity. Omission of the last gemcitabine dose
did not appear to decrease the response rate, and it may be
advisable to change the gemcitabine-cisplatin schedule to
gemcitabine at days 1 and 8 and cisplatin at day 1 or 2 and
repeat this every three weeks.
In conclusion, gemcitabine is an important agent for
improved management of several relatively chemoresistant
cancer types, both with respect to antitumor activity and to
clinical benefit and patients’ tolerability. Further studies con-
cerning the single agent as well as the combination with other
anticancer drugs deserve high priority. These studies might
well benefit from thorough knowledge of the metabolism,
mechanism(s) of action, resistance profile, and the mode of
interaction of gemcitabine with the other compounds. 
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